HomeAbout

TL;DR CNBC


Pfizer beats revenue estimates, raises profit outlook on cost cuts and smaller-than-feared drop in Covid drug sales - TL;DR CNBC

Pfizer beats revenue estimates, raises profit outlook on cost cuts and smaller-than-feared drop in Covid drug sales

Publishing timestamp: 2024-05-01 13:22:48


Summary

Pfizer reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefiting from cost-cutting, strong non-Covid product sales, and smaller-than-feared drop in sales of its Covid antiviral pill Paxlovid. The company is confident in its business and ability to slash costs, with shares rising more than 4% on the news.


Sentiment: POSITIVE

Tickers: PFE

Keywords: businesspfizer incpharmaceuticalsearningsbiotechnologybreaking newsdividendsunited stateshealth care industrybiotech and pharmaceuticalsspin-offsearnings reportsbusiness news

Source: https://www.cnbc.com/2024/05/01/pfizer-pfe-earnings-q1-2024.html


Developed by Leo Phan